# The Efficacy and Safety of DLBS3233 in Adults With Prediabetes

Study · id `cardio:ct-nct07937449` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07937449](<https://clinicaltrials.gov/study/NCT07937449>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07937449

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

## Technical summary

Registry record NCT07937449. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-07 (actual); primary completion 2026-10-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT07937449, source copy `cardio:ctgov-nct07937449-2026-11-16`, retrieved 2026-11-18)
- Started: 2025-07-07 (actual) (ClinicalTrials.gov record NCT07937449, source copy `cardio:ctgov-nct07937449-2026-11-16`, retrieved 2026-11-18)
- Primary completion: 2026-10-15 (actual) (ClinicalTrials.gov record NCT07937449, source copy `cardio:ctgov-nct07937449-2026-11-16`, retrieved 2026-11-18)
- Completion: 2026-10-15 (actual) (ClinicalTrials.gov record NCT07937449, source copy `cardio:ctgov-nct07937449-2026-11-16`, retrieved 2026-11-18)
- Countries: Indonesia (ClinicalTrials.gov record NCT07937449, source copy `cardio:ctgov-nct07937449-2026-11-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07937449-2026-11-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: The Efficacy and Safety of DLBS3233 in Adults With Prediabetes
- Condition: Prediabetes
- Intervention (Drug): DLBS3233
- Intervention (Drug): Metformin XR
- Lead sponsor: Dexa Medica Group
- Lead sponsor class: INDUSTRY
- Collaborator: PT Equilab International
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry lists this organization as the lead sponsor: Dexa Medica Group (`cardio:org-dexa-medica-group`)

## Provenance

Content hash: df26dfc6d26a1057bebeab4a20514452dfe2451a54d95669be7d801040674497
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
